39.00
-0.66 (-1.66%)
| Previous Close | 39.66 |
| Volume | 304,092 |
| Price / Sales | 90.77 |
| Price / Book | 4.58 |
| 52 Weeks Range |
| Diluted EPS (TTM) | -3.82 |
| Total Debt/Equity (MRQ) | 2.74% |
| Current Ratio (MRQ) | 31.01 |
| Operating Cash Flow (TTM) | -67.45 M |
| Levered Free Cash Flow (TTM) | -47.00 M |
| Return on Assets (TTM) | -22.89% |
| Return on Equity (TTM) | -33.14% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Bullish |
| Biotechnology (Global) | Mixed | Bullish | |
| Stock | Rapport Therapeutics, Inc. | Mixed | Bullish |
AIStockmoo Score
| Analyst Consensus | NA |
| Insider Activity | -1.5 |
| Price Volatility | 2.0 |
| Technical Moving Averages | -2.5 |
| Technical Oscillators | -0.5 |
| Average | -0.63 |
|
Rapport Therapeutics Inc is a clinical-stage biotechnology company dedicated to the discovery and development of small-molecule precision medicines for patients with neurological or psychiatric disorders. The company's portfolio of programs from its RAP technology platform includes RAP-219, an investigational small molecule being developed as a therapy for focal onset seizures, primary generalized tonic-clonic seizures, and bipolar mania. Additionally, it has two discovery-stage nicotinic acetylcholine receptor (nAChR) programs stemming from its RAP technology platform: one being developed for the treatment of chronic pain, and the second, being developed for the treatment of hearing disorders. Geographically, the company operates in the United States. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Core |
| % Held by Insiders | 6.28% |
| % Held by Institutions | 105.23% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Trv Gp V, Llc | 30 Jun 2026 | 6,280,525 |
| Sofinnova Investments, Inc. | 30 Jun 2026 | 1,904,408 |
| Johnson & Johnson | 30 Jun 2026 | 1,784,517 |
| Polar Capital Holdings Plc | 30 Jun 2026 | 1,608,514 |
| Trv Gp Vi, Llc | 30 Jun 2026 | 969,218 |
No data within this time range.
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| CEESAY ABRAHAM | - | 46.09 | -8,210 | -378,399 |
| Aggregate Net Quantity | -8,210 | |||
| Aggregate Net Value ($) | -378,399 | |||
| Aggregate Avg. Buy ($) | - | |||
| Aggregate Avg. Sell ($) | 46.09 | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| CEESAY ABRAHAM | Officer | 08 Sep 2026 | Automatic sell (-) | 8,210 | 46.09 | 378,399 |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |